欢迎访问西安瑞禧生物技术有限公司官方网站

图片名

全国订购热线:
18966759382

首页 > 新闻资讯 > 技术资讯

技术资讯
行业新闻 市场活动 技术资讯

「同位素标记抑制剂」CAS:1184991-14-7|Clofibric acid-d4

作者:瑞禧生物 发布时间:2025-06-30 09:16:59 次浏览

生物活性:Clofibric acid-d4 is the deuterium labeled Clofibric acid (HY-B1415). Clofibric acid also is an herbicideClofibric acid (Chlorofibrinic acid) is an orally active PPARα agonist. Clofibric acid inhibits the fimbriation of Escherichia coli. Clofibric acid increases SOD activity. Clofibric acid lowers blood lipids and prevents experimental pyelonephritis. Clofibric acid has anticancer activity against ovarian cancer. Clofibric acid is also a herbicide. Clofibric acid is used in ovarian cancer, liver cancer, obesity, and urinary tract infection research[1][2][3][4][5][6][7][8][9].
体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
瑞禧生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Clofibric acid-d4 相关抗体:
PPAR alpha Antibody
PPAR gamma Antibody
SOD2 Antibody (YA071)
PPAR gamma Antibody (YA122)
SOD2 Antibody (YA670)
MRP2 Antibody
SOD1 Antibody
Elongation factor 2 Antibody (YA962)
Elongation factor 2 Antibody (YA964)
PU.1/SPI1 Antibody (YA1116)
Sulfadimidine Antibody (YA906)
Elongation factor 2 Antibody (YA963)
Anthrax Protective gen Antibody (YA1060)
PGC1 beta Antibody (YA1411)
Elongation factor 1 gamma Antibody (YA2004)
Pulmonary Surfactant Associated Protein D Antibody (YA2107)
Cathelicidin Antibody (YA2380)
Superoxide Dismutase 3 Antibody (YA2420)
Elongation Factor Ts Antibody (YA2524)
Elongation Factor 1A2 Antibody (YA2879)
BPI Antibody (YA3068)
MetRS Antibody (YA3196)
分子量:218.67
Formula:C10H7D4ClO3
CAS 号:1184991-14-7
非标记 CAS:882-09-7
中文名称:氯贝酸 d4
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (535 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Forman BM, et, al. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4312-7.
 [Content Brief]
[2]. Salgado R, et, al. Biodegradation of clofibric acid and identification of its metabolites. J Hazard Mater. 2012 Nov 30;241-242:182-9.
 [Content Brief]
[3]. Kawashima Y, et, al. Increased activity of stearoyl-CoA desaturation in liver from rat fed clofibric acid. Biochim Biophys Acta. 1982 Dec 13;713(3):622-8.
 [Content Brief]
[4]. Yokoyama Y, et al. Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer. Mol Cancer Ther. 2007 Apr;6(4):1379-86.
 [Content Brief]
[5]. Bécuwe P, et al. Effects of the peroxisome proliferator clofibric acid on superoxide dismutase expression in the human HepG2 hepatoma cell line. Biochem Pharmacol. 1999 Sep 15;58(6):1025-33.
 [Content Brief]
[6]. Blaauboer B J, et al. The effect of beclobric acid and clofibric acid on peroxisomal β-oxidation and peroxisome proliferation in primary cultures of rat, monkey and human hepatocytes. Biochemical Pharmacology, 1990, 40(3): 521-528.
[7]. Cleary MP, et al. Effect of long-term clofibric acid treatment on serum and tissue lipid and cholesterol levels in obese Zucker rats. Atherosclerosis. 1987 Jul;66(1-2):107-12.
 [Content Brief]
[8]. Balagué CE, et al. Clofibric and ethacrynic acids prevent experimental pyelonephritis by Escherichia coli in mice. FEMS Immunol Med Microbiol. 2004 Nov 1;42(3):313-9.
 [Content Brief]
[9]. Yamakawa Y, et al. A single pretreatment with clofibric acid attenuates carbon tetrachloride-induced necrosis, but not steatosis, in rat liver. Food Chem Toxicol. 2020 Nov;145:111591.
 [Content Brief]